IMC-4022

N/A

Report date: 2023/08/11 17:52:22

Base Information

Drug NameIMC-4022

Drug Alias NameIMC-4022

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsCarcinoma, Renal Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesImmuneCyte Inc

China Registration ClassN/A

Develop Information

Active CompaniesImmuneCyte Inc

Inactive CompaniesN/A

Active IndicationsCarcinoma, Renal Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A